* GENOWAY *
1999 - Rhône-Alpes
Lyon
www.genoway.com Contract, Research
Key words: Gene amplification, Clonal animal, Mouse, Toxicology tests
Mission: to provide third parties with customized and ready-to-use genetically modified mouse and rat models (Knock-out, conditional Knock-out, Knock-in, RNAi, humanized, transgenic mice and rats)
Clients: Research labs
info@genoway.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Spin-off |
Managing Dir.: Fraichard (Alexandre) [co-founder, born 1968, Ph.D. molecular biology (1997), Normale Sup (Lyon), MBA]
Sc.Dir.:
Fin.Dir.: de Poncins (Gilles) [co-founder, Science Po (Paris), MBA, ex-Renault, Qualis, Sofecome]
BusDev: Thiam (Kader)
Financers: Dassault Développement, CDC E.I., Finoway (Qualis), Rhône Alpes Création, Public | Turnover (M€) : 3.5 (2006)
Total funding (M€) : 10.8
Last funding (M€) : 1.1
Focus : Genome
Position : Subcontractor
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .06 | Financing (no interest loan) : 7.1 M€, by Oseo for IT-Diab programme (drug and diag) with Genfit, SpiBio, Roowin and Academic Institutions, over 5 years | DEBT | [9 years] |
| 2007 .05 | Seed financing : 1.1 M€, by NGFN (National Genome Research Network) in Germany | SFIN | [8 years] |
| 2007 .05 | Listing on Alternext : 6.2 M€ (23% of shares) | PBO | [8 years] |
| 2006 .05 | Partnering distribution agreement with Charles River (USA market, co-promotion) | MKTG | [7 years] |
| 2005 .00 | Acquisition of Murinus (Germany) | ACQ+ | [6 years] |
| 2004 .09 | 2nd round-financing : 4.0 M€, led by CDC Entreprises, Siparex Ventures | RFINB | [5 years] |
| 2003 .04 | 1st round-financing : 3.5 M€, led by Dassault Developpement, with Qualis, Rhône Alpes Création | RFINA | [4 years] |
| 1999 .03 | Company founded by Alexandre Fraichard and Gilles de Poncins, as a spin-off from Normale Sup (Lyon) | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
